Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1607

BMS936558-hIgG1

Home » Antibodies » BMS936558-hIgG1

Background of BMS936558-hIgG1

PD-1 (programmed death Receptor 1), also known as CD279 (differentiated cluster 279), is an important immunosuppressive molecule. Regulates the immune system and promotes self-tolerance by down-regulating the immune system's response to human cells, as well as by suppressing T cell inflammatory activity. Nivolumab can specifically attach to the PD-1 receptor of T cells and prevent T cell inactivation, thereby blocking the immune escape of cancer cells and improving the immune stem's ability to kill cancer cells.

Specifications

Catalog Number:
KB-1607
Antibody Name:
BMS936558-hIgG1
Isotype:
Human IgG1,kappa
FC Muations:
Target:
PD1
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Kortnye Maureen Smith , Jayesh Desai . Nivolumab for the treatment of colorectal cancer.Expert Rev Anticancer Ther. 2018 Jul;18(7):611-618.
  2. Pengpeng Liu , Xiangyu Pan , Chong Chen , Ting Niu , Xiao Shuai , Jian Wang , Xuelan Chen , Jiazhuo Liu , Yong Guo , Liping Xie , Yu Wu , Yu Liu , Ting Liu .Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.Blood. 2020 Mar 12;135(11):826-833.